Pharming Group N.V. Navigates Strategic Shift Amid Heavy Reliance on RUCONEST
Pharming Group N.V., a major player in the biotech field, has announced a pivotal shift in their strategic operations. This move comes in response to their heavy dependence on the drug RUCONEST, which accounts for a significant portion of their revenue. The company is steering towards diversification by focusing on the rollout of Joenja across multiple countries, while addressing pressing risks like intense competition and supply chain vulnerabilities. Thousands of employees may be affected as the company restructures and reallocates resources to mitigate these challenges and embrace new opportunities.
Apr 2